PCN9 Modeling Lifetime Effectiveness of Denosumab Versus Placebo in Men With Castration Resistant Prostate Cancer (CRPC) at High Risk of Developing Bone Metastasis (BM)

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1204
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn153 - Cost-Effectiveness Analysis of Apalutamide for Treatment in Non- Metastasis Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians

Clinical Genitourinary Cancer
OncologyUrology
2015English

Guideline Adherence in Docetaxel Treatment of Castration Resistant Prostate Cancer (CRPC) Patients in a Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2010English

Quantitative Measurement of 219Rn Radioactivity in Exhaled Breath From Patients With Bone Metastasis of Castration-Resistant Prostate Cancer Treated With 223RaCl2

EJNMMI Physics
InstrumentationNuclear MedicineRadiologyRadiationImagingBiomedical Engineering
2019English

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

JAMA Oncology
Cancer ResearchOncology
2020English

Treatment of Castration-Resistant Prostate Cancer and Bone Metastases With Radium-223 Dichloride

International Journal of Urological Nursing
UrologyNursingNephrology
2014English

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

The Lancet Oncology
Oncology
2013English

A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy